Modulation of duodenal and jejunal microbiota by rifaximin in mice with CCl4-induced liver fibrosis

被引：0
作者：
Kazuhiko Ikeuchi
Takeya Tsutsumi
Aya Ishizaka
Taketoshi Mizutani
Ayako Sedohara
Michiko Koga
Satoru Tamaoki
Hiroshi Yotsuyanagi
机构：
[1] The University of Tokyo,Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science
[2] The University of Tokyo,Department of Infection Control and Prevention
[3] ASKA Pharmaceutical Co.,Medical Affairs Department
[4] Ltd.,undefined
来源：
Gut Pathogens | / 15卷
关键词：
Microbiome; Liver fibrosis; Small intestine; Hepatic encephalopathy; Lactobacillaceae; Firmicutes; Bacteroidetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 231 条
[1]  
Adachi JA(2006)Rifaximin: a novel Nonabsorbed Rifamycin for gastrointestinal disorders Clin Infect Dis 42 541-547
[2]  
DuPont HL(2005)Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential Chemotherapy 51 36-66
[3]  
Scarpignato C(2016)Hepatic encephalopathy N Engl J Med 375 1660-1670
[4]  
Pelosini I(2020)The gut-liver axis in liver disease: Pathophysiological basis for therapy J Hepatol 72 558-577
[5]  
Wijdicks EF(2021)Leaky gut and gut-liver Axis in Liver Cirrhosis: clinical studies update Gut Liver 15 666-676
[6]  
Albillos A(2018)Clinical impact of microbiome in patients with decompensated cirrhosis World J Gastroenterol 24 3813-3820
[7]  
de Gottardi A(2011)Characterization of fecal microbial communities in patients with liver cirrhosis Hepatology 54 562-572
[8]  
Rescigno M(2014)Alterations of the human gut microbiome in liver cirrhosis Nature 513 59-64
[9]  
Fukui H(2016)Impaired gut-liver-brain axis in patients with Cirrhosis Sci Rep 6 26800-18.e2
[10]  
Oikonomou T(2019)Predicting clinical outcomes of cirrhosis patients with hepatic encephalopathy from the fecal microbiome Cell Mol Gastroenterol Hepatol 8 301-489
12345678910